Altre lingue BeiGene, Ltd.

Azioni

BGNE

US07725L1026

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 25/06/2024			Variaz. 5gg	Var. 1 gen.
151 ^USD	-5,13%		-2,40%	-16,28%

20/06	Un insider di Beigene ha venduto azioni per un valore di 368.162 dollari, secondo un recente documento della SEC	MT
14/06	BeiGene presenterà i nuovi dati dello studio SEQUOIA che valuta BRUKINSA® più Venetoclax nella LLC/SLL di prima linea ad alto rischio all'EHA2024	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Beigene Insider Sold Shares Worth $368,162, According to a Recent SEC Filing	20/06
BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024	17/06
BeiGene, Ltd.(SHSE:688235) added to Shanghai Stock Exchange Health Care Sector Index	17/06
BeiGene présentera à l’EHA2024 de nouvelles données sur l’étude SEQUOIA évaluant la bithérapie BRUKINSA® plus vénétoclax dans le traitement de première intention de patients atteints de LLC/PLL à haut risque	15/06
EHA2024: BeiGene präsentiert neue Daten der SEQUOIA-Studie zu BRUKINSA® plus Venetoclax für die Erstlinienbehandlung von Hochrisiko-CLL/SLL	15/06
BeiGene Says New Phase 3 Brukinsa Data Show 'Promising' Efficacy in Leukemia, Lymphoma	14/06
BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024	14/06
BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024	14/06
BeiGene and NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA® (Zanubrutinib) Partnership in the Middle East and Africa (MENA) Region	14/06
Beijing Gene Announces Dose the First Five Patients in Its First-In-Human Phase 1 Trial to Evaluate BG-68501	12/06
Beigene Issues Shares Under Incentive Schemes	12/06
Zymeworks Says China's Health Regulator Accepts Biologics License Application for Cancer Therapy	10/06
BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference	04/06
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS First in Human Study	28/05
BriaCell Therapeutics, BeiGene Partner to Test Combination of Companies' Cancer Treatments	28/05
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study	28/05
BriaCell Therapeutics Corp. Announces Clinical Supply Agreement with BeiGene, Ltd. for Bria-OTS First in Human Study	28/05
BeiGene Says Studies Highlight Effectiveness, Safety of Lymphoma Drug Brukinsa	24/05
BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL	24/05
BeiGene, Ltd. Announces New Analyses for BRUKINSA® (zanubrutinib) At ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL	24/05

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue BeiGene, Ltd.

Azioni

BGNE

US07725L1026

Altre lingue

Filtri